WallStreetZenWallStreetZen

NYSE: GMED
Globus Medical Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for GMED

Based on 11 analysts offering 12 month price targets for Globus Medical Inc

Min Forecast
$80.00+14.19%
Avg Forecast
$96.91+38.32%
Max Forecast
$115.00+64.15%

Should I buy or sell GMED stock?

Based on 11 analysts offering ratings for Globus Medical Inc.

Strong Buy
Strong Buy
8 analysts 72.73%
Buy
1 analysts 9.09%
Hold
2 analysts 18.18%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Buy" agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their GMED stock forecasts and price targets.

GMED stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-11
lockedlocked$00.00+00.00%2025-02-24
lockedlocked$00.00+00.00%2025-02-21
lockedlocked$00.00+00.00%2025-02-21
lockedlocked$00.00+00.00%2025-01-10
Bank of America
Top 4%
97
HoldUpgrades$97.00+38.45%2025-01-09
Roth MKM
Bottom 15%
15
Strong BuyMaintains$115.00+64.15%2024-12-17
BTIG
Top 8%
93
Strong BuyMaintains$91.00+29.89%2024-12-12
Morgan Stanley
Bottom 11%
11
Strong BuyUpgrades$100.00+42.73%2024-12-02
RBC Capital
Bottom 14%
14
BuyMaintains$92.00+31.32%2024-11-06

1 of 2

Forecast return on equity

Is GMED forecast to generate an efficient return?

Company
14.95%
Industry
23.05%
Market
61.93%
GMED's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GMED forecast to generate an efficient return on assets?

Company
11.89%
Industry
12.27%
GMED is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GMED earnings per share forecast

What is GMED's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$3.45+353.51%
Avg 2 year Forecast
$3.97+422.22%
Avg 3 year Forecast
$4.54+497.37%
GMED's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

GMED revenue forecast

What is GMED's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$2.7B+6.53%
Avg 2 year Forecast
$2.9B+13.9%
Avg 3 year Forecast
$3.1B+21.41%
GMED's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GMED earnings growth forecast

How is GMED forecast to perform vs Medical Devices companies and vs the US market?

Company
128.95%
Industry
24.35%
Market
23.6%
GMED's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
GMED's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
GMED's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

GMED revenue growth forecast

How is GMED forecast to perform vs Medical Devices companies and vs the US market?

Company
6.75%
Industry
8.1%
Market
10.62%
GMED's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GMED's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GMED vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
GMED$70.06$96.91+38.32%Strong Buy
PEN$277.22$297.15+7.19%Strong Buy
MASI$152.07$201.00+32.18%Strong Buy
SNN$26.16$27.00+3.21%Hold
BIO$244.98$400.33+63.41%Buy
View Top Medical Device Stocks

Globus Medical Stock Forecast FAQ

Is Globus Medical Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 11 Wall Street analysts covering (NYSE: GMED) stock is to Strong Buy GMED stock.

Out of 11 analysts, 8 (72.73%) are recommending GMED as a Strong Buy, 1 (9.09%) are recommending GMED as a Buy, 2 (18.18%) are recommending GMED as a Hold, 0 (0%) are recommending GMED as a Sell, and 0 (0%) are recommending GMED as a Strong Sell.

If you're new to stock investing, here's how to buy Globus Medical stock.

What is GMED's earnings growth forecast for 2025-2027?

(NYSE: GMED) Globus Medical's forecast annual earnings growth rate of 128.95% is forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 24.35%, and it is also forecast to beat the US market's average forecast earnings growth rate of 23.6%.

Globus Medical's earnings in 2025 is $102,984,000.On average, 9 Wall Street analysts forecast GMED's earnings for 2025 to be $474,064,798, with the lowest GMED earnings forecast at $466,266,187, and the highest GMED earnings forecast at $481,395,768. On average, 9 Wall Street analysts forecast GMED's earnings for 2026 to be $545,889,047, with the lowest GMED earnings forecast at $533,661,594, and the highest GMED earnings forecast at $590,053,670.

In 2027, GMED is forecast to generate $624,439,082 in earnings, with the lowest earnings forecast at $605,183,251 and the highest earnings forecast at $653,322,828.

What is GMED's revenue growth forecast for 2025-2027?

(NYSE: GMED) Globus Medical's forecast annual revenue growth rate of 6.75% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.1%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.62%.

Globus Medical's revenue in 2025 is $2,519,355,000.On average, 8 Wall Street analysts forecast GMED's revenue for 2025 to be $369,156,006,483, with the lowest GMED revenue forecast at $367,920,469,859, and the highest GMED revenue forecast at $371,183,645,458. On average, 8 Wall Street analysts forecast GMED's revenue for 2026 to be $394,690,063,267, with the lowest GMED revenue forecast at $392,206,198,646, and the highest GMED revenue forecast at $395,996,158,757.

In 2027, GMED is forecast to generate $420,697,675,946 in revenue, with the lowest revenue forecast at $418,552,989,029 and the highest revenue forecast at $425,416,317,264.

What is GMED's forecast return on assets (ROA) for 2025-2027?

(NYSE: GMED) forecast ROA is 11.89%, which is lower than the forecast US Medical Devices industry average of 12.27%.

What is GMED's Price Target?

According to 11 Wall Street analysts that have issued a 1 year GMED price target, the average GMED price target is $96.91, with the highest GMED stock price forecast at $115.00 and the lowest GMED stock price forecast at $80.00.

On average, Wall Street analysts predict that Globus Medical's share price could reach $96.91 by Apr 11, 2026. The average Globus Medical stock price prediction forecasts a potential upside of 38.32% from the current GMED share price of $70.06.

What is GMED's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSE: GMED) Globus Medical's current Earnings Per Share (EPS) is $0.76. On average, analysts forecast that GMED's EPS will be $3.45 for 2025, with the lowest EPS forecast at $3.39, and the highest EPS forecast at $3.50. On average, analysts forecast that GMED's EPS will be $3.97 for 2026, with the lowest EPS forecast at $3.88, and the highest EPS forecast at $4.29. In 2027, GMED's EPS is forecast to hit $4.54 (min: $4.40, max: $4.75).

What is GMED's forecast return on equity (ROE) for 2025-2027?

(NYSE: GMED) forecast ROE is 14.95%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.